Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3F427)

• Drug Name: EphB4-131 Drug Info
• Synonyms: EphB4 neutralizing antibody, Vasgene

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Investigative	[1]

• Cross-matching ID: TTD Drug ID: DM3F427

Molecule-Related Drug Atlas

Drug(s) Targeting Ephrin type-B receptor 4 (EPHB4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
KD019	DMEFW3G	Brain metastases	2D50	Phase 2	[2]
PMID23489211C20	DMDYC4J	Discovery agent	N.A.	Investigative	[3]
PMID19788238C66	DMCVJK9	Discovery agent	N.A.	Investigative	[4]
TG-100435	DMIR3X2	Discovery agent	N.A.	Investigative	[5]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Ephrin type-B receptor 4 (EPHB4)	TTI4ZX2	EPHB4_HUMAN	Not Available	[1]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1833).
• [2] XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib. J Thorac Oncol. 2012 Jan;7(1):219-26.
• [3] Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47.
• [4] Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46.
• [5] Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinas... Bioorg Med Chem Lett. 2007 Feb 1;17(3):602-8.